Claims
- 1. A method of determining whether a patient is suffering from or at risk for developing a bone condition, the method comprising:
providing a test sample from a patient suspected of suffering from or being at risk for developing a bone condition, and quantifying an expression level of an LRP-1 gene, wherein the expression level of the LRP-1 gene in the test sample, if different from that in a normal sample, indicates that the patient is suffering from or at risk for developing a bone condition.
- 2. The method of claim 1, wherein the test sample is prepared from a bone tissue.
- 3. A method of determining whether a patient is suffering from or at risk for developing a bone condition, the method comprising:
providing a test sample from a patient suspected of suffering from or being at risk for developing a bone condition, and quantifying an activity of an LRP-1 protein, wherein the activity of the LRP-1 protein in the test sample, if different from that in a normal sample, indicates that the patient is suffering from or at risk for developing a bone condition.
- 4. The method of claim 3, wherein the test sample is prepared from a bone tissue.
- 5. A method of identifying a candidate compound for treating a bone condition, the method comprising:
contacting a compound with a cell expressing an LRP-1 gene, and quantifying an expression level of the LRP-1 gene in the cell, wherein the expression level of the LRP-1 gene in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.
- 6. The method of claim 5, wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.
- 7. The method of claim 6, wherein the cell is a SaOS-2 cell.
- 8. The method of claim 5, wherein the cell is an osteoclast cell.
- 9. A method of identifying a candidate compound for treating a bone condition, the method comprising:
contacting a compound with a cell expressing an LRP-1 gene encoding an LRP-1 protein, and quantifying an activity of the LRP-1 protein in the cell, wherein the activity of the LRP-1 protein in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.
- 10. The method of claim 9, wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.
- 11. The method of claim 10, wherein the cell is a SaOS-2 cell.
- 12. The method of claim 9, wherein the cell is an osteoclast cell.
- 13. A method of treating a bone condition, the method comprising modulating a level of an LRP-1 protein in bone cells.
- 14. The method of claim 13, wherein the level of the LRP-1 protein is modulated by providing and expressing a nucleic acid encoding an LRP-1 protein.
- 15. The method of claim 14, wherein the nucleic acid is expressed in the bone cells.
- 16. The method of claim 13, wherein the level of the LRP-1 protein is modulated by providing an LRP-1 protein.
- 17. The method of claim 16, wherein the LRP-1 protein is introduced into the bone cells.
- 18. The method of claim 13, wherein the level of the LRP-1 protein is modulated by providing and expressing a nucleic acid complementary to a sequence encoding an LRP-1 protein.
- 19. The method of claim 18, wherein the nucleic acid is expressed in the bone cells.
- 20. A method of treating a bone condition, the method comprising modulating an activity of an LRP-1 protein in bone cells.
- 21. The method of claim 20, wherein the activity of the LRP-1 protein is modulated by providing an agonist of the LRP-1 protein.
- 22. The method of claim 21, wherein the agonist is introduced into the bone cells.
- 23. The method of claim 20, wherein the activity of the LRP-1 protein is modulated by providing an antagonist of the LRP-1 protein.
- 24. The method of claim 23, wherein the antagonist is introduced into the bone cells.
- 25. The method of claim 20, wherein the activity of the LRP-1 protein is modulated by providing an antibody against the LRP-1 protein.
- 26. The method of claim 25, wherein the antibody is introduced into the bone cells.
- 27. A method of determining whether a patient is suffering from or at risk for developing a bone condition, the method comprising:
providing a test sample from a bone tissue of a patient suspected of suffering from or being at risk for developing a bone condition, and quantifying an expression level of an LRP-2 gene, wherein the expression level of the LRP-2 gene in the test sample, if different from that in a normal sample, indicates that the patient is suffering from or at risk for developing a bone condition.
- 28. A method of determining whether a patient is suffering from or at risk for developing a bone condition, the method comprising:
providing a test sample from a bone tissue of a patient suspected of suffering from or being at risk for developing a bone condition, and quantifying an activity of an LRP-2 protein, wherein the activity of the LRP-2 protein in the test sample, if different from that in a normal sample, indicates that the patient is suffering from or at risk for developing a bone condition.
- 29. A method of identifying a candidate compound for treating a bone condition, the method comprising:
contacting a compound with a bone cell expressing an LRP-2 gene, and quantifying an expression level of the LRP-2 gene in the cell, wherein the expression level of the LRP-2 gene in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.
- 30. The method of claim 29, wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.
- 31. The method of claim 30, wherein the cell is a SaOS-2 cell.
- 32. The method of claim 29, wherein the cell is an osteoclast cell.
- 33. A method of identifying a candidate compound for treating a bone condition, the method comprising:
contacting a compound with a bone cell expressing an LRP-2 gene encoding an LRP-2 protein, and quantifying an activity of the LRP-2 protein in the cell, wherein the activity of the LRP-2 protein in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone condition.
- 34. The method of claim 33, wherein the cell is an osteoblast cell, osteoblast-like cell, or osteocyte.
- 35. The method of claim 34, wherein the cell is a SaOS-2 cell.
- 36. The method of claim 33, wherein the cell is an osteoclast cell.
- 37. A method of treating a bone condition, the method comprising modulating a level of an LRP-2 protein in bone cells.
- 38. The method of claim 37, wherein the level of the LRP-2 protein is modulated by introducing into and expressing in the bone cells a nucleic acid encoding an LRP-2 protein.
- 39. The method of claim 37, wherein the level of the LRP-2 protein is modulated by introducing into the bone cells an LRP-2 protein.
- 40. The method of claim 37, wherein the level of the LRP-2 protein is modulated by introducing into and expressing in the bone cells a nucleic acid complementary to a sequence encoding an LRP-2 protein.
- 41. A method of treating a bone condition, the method comprising modulating an activity of an LRP-2 protein in bone cells.
- 42. The method of claim 41, wherein the activity of the LRP-2 protein is modulated by introducing into the bone cells an agonist of the LRP-2 protein.
- 43. The method of claim 41, wherein the activity of the LRP-2 protein is modulated by introducing into the bone cells an antagonist of the LRP-2 protein.
- 44. The method of claim 41, wherein the activity of the LRP-2 protein is modulated by introducing into the bone cells an antibody against the LRP-2 protein.
- 45. A method of determining whether a subject is suffering from or at risk for developing a bone or cartilage condition, the method comprising:
providing a test sample from a subject, and determining a level of interaction between a lactoferrin polypeptide and an LRP-1 or LRP-2 protein in the test sample, wherein the level of the interaction between the lactoferrin polypeptide and the LRP-1 or LRP-2 protein in the test sample, if different from that in a normal sample, indicates that the subject is suffering from or at risk for developing a bone or cartilage condition.
- 46. The method of claim 45, wherein the test sample is prepared from a bone or cartilage tissue.
- 47. A method of identifying a candidate compound for treating a bone or cartilage condition, the method comprising:
introducing a compound to a system containing a lactoferrin polypeptide and an LRP-1 or LRP-2 protein, and determining a level of interaction between the lactoferrin polypeptide and the LRP-1 or LRP-2 protein, wherein the level of the interaction between the lactoferrin polypeptide and the LRP-1 or LRP-2 protein in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone or cartilage condition.
- 48. The method of claim 47, wherein the sample contains an osteoblastic, osteoclastic or fibroblastic cell, or a chondrocyte.
- 49. A method of treating a bone or cartilage condition, the method comprising modulating interaction between a lactoferrin polypeptide and an LRP-1 or LRP-2 protein in bone or cartilage cells.
- 50. The method of claim 49, wherein the interaction between the lactoferrin polypeptide and the LRP-1 or LRP-2 protein is modulated by providing an agonist of the LRP-1 or LRP-2 protein.
- 51. The method of claim 50, wherein the agonist is introduced into the bone or cartilage cells.
- 52. The method of claim 50, wherein the agonist is an exogenous lactoferrin polypeptide.
- 53. The method of claim 52, wherein the exogenous lactoferrin polypeptide is introduced into the bone or cartilage cells.
- 54. The method of claim 49, wherein the interaction between the lactoferrin polypeptide and the LRP-1 or LRP-2 protein is modulated by providing an antagonist of the LRP-1 or LRP-2 protein.
- 55. The method of claim 54, wherein the antagonist is introduced into the bone or cartilage cells.
- 56. The method of claim 54, wherein the antagonist is a receptor-associated protein.
- 57. The method of claim 56, wherein the receptor-associated protein is introduced into the bone or cartilage cells.
- 58. A method of determining whether a subject is suffering from or at risk for developing a bone or cartilage condition, the method comprising:
providing a test sample from a subject, and determining a level of interaction between a lactoferrin polypeptide and a p42/44 MAP kinase in the test sample, wherein the level of the interaction between the lactoferrin polypeptide and the p42/44 MAP kinase in the test sample, if different from that in a normal sample, indicates that the subject is suffering from or at risk for developing a bone or cartilage condition.
- 59. The method of claim 58, wherein the test sample is prepared from a bone or cartilage tissue.
- 60. A method of identifying a candidate compound for treating a bone or cartilage condition, the method comprising:
introducing a compound with a system containing a lactoferrin polypeptide and a p42/44 MAP kinase, and determining a level of interaction between the lactoferrin polypeptide and the p42/44 MAP kinase, wherein the level of the interaction between the lactoferrin polypeptide and the p42/44 MAP kinase in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a bone or cartilage condition.
- 61. The method of claim 60, wherein the sample contains an osteoblastic, osteoclastic or fibroblastic cell, or a chondrocyte.
- 62. A method of treating a bone or cartilage condition, the method comprising modulating interaction between a lactoferrin polypeptide and a p42/44 MAP kinase in bone or cartilage cells.
- 63. The method of claim 62, wherein the interaction between the lactoferrin polypeptide and the p42/44 MAP kinase is modulated by providing an agonist of the p42/44 MAP kinase.
- 64. The method of claim 63, wherein the agonist is introduced into the bone or cartilage cells.
- 65. The method of claim 63, wherein the agonist is an exogenous lactoferrin polypeptide.
- 66. The method of claim 65, wherein the exogenous lactoferrin polypeptide is introduced into the bone or cartilage cells.
- 67. The method of claim 62, wherein the interaction between the lactoferrin polypeptide and the p42/44 MAP kinase is modulated by providing an antagonist of the p42/44 MAP kinase.
- 68. The method of claim 67, wherein the antagonist is introduced into the bone or cartilage cells.
- 69. The method of claim 67, wherein the antagonist is an inhibitor of a p42/44 MAP kinase.
- 70. The method of claim 69, wherein the inhibitor of the p42/44 MAP kinase is introduced into the bone or cartilage cells.
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application No. 60/380,227, filed May 13, 2002, and U.S. Provisional Application No. 60/463,419, filed Apr. 16, 2003, the contents of which are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60380227 |
May 2002 |
US |
|
60463419 |
Apr 2003 |
US |